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Introduction
It  is  has  long  been  known  that  sustained  catecholaminergic 
stress promotes heart failure (Cohn et al., 1984; MERIT-HF 
Study Group, 1999), whereas short repetitive catecholaminer-
gic stimulation as occurs during physical exercise training 
exerts cardioprotective effects (Keteyian et al., 2010). Thus, a 
deeper understanding of the downstream mediators of catechol-
amine signaling may unveil maladaptive versus adaptive mo-
lecular pathways, leading to new strategies for therapeutically 
manipulating the catecholaminergic pathway.
The G protein GS couples -adrenergic receptors (-ARs) 
to adenylyl cyclase, generating cAMP, which activates PKA 
(Wettschureck and Offermanns, 2005). PKA, in turn, phosphory-
lates numerous proteins involved in excitation-contraction 
coupling (Bers, 2002). However, sustained catecholaminergic 
signaling, a hallmark of heart failure, results in -AR down-
regulation, uncoupling of adenylyl cyclase from -ARs, and   
reduced PKA activity (Fowler et al., 1986; Hausdorff et al., 
1990; Rockman et al., 1996; Osadchii, 2007; Rajagopal et al., 
2010). In contrast to PKA, calcium/CaM-dependent protein 
kinase II (CaMKII) remains activated under sustained -AR 
stimulation (Wang et al., 2004). Originally, it was thought that 
CaMKII activation resulted from PKA-mediated increases in 
cytosolic calcium levels (Grimm and Brown, 2010), but recent 
evidence suggests the existence of PKA-independent mecha-
nisms of CaMKII activation (Zhu et al., 2003; Erickson et al., 
2008; Timmins et al., 2009; Mangmool et al., 2010; Métrich 
et al., 2010; Wagner et al., 2011).
Class II histone deacetylases (HDACs; HDACs 4, 5, 7, 
and 9) function as nodal regulators of striated muscle stress 
responses by linking upstream calcium-dependent protein kinases 
to downstream gene regulatory programs involved in myocyte 
hypertrophy, fibrosis, and metabolism (Czubryt and Olson, 
2004; Backs and Olson, 2006; McGee and Hargreaves, 2010; 
Kehat et al., 2011). Class IIa HDACs share a common structure 
with a C-terminal catalytic domain and an N-terminal regulatory 
domain that interacts with transcription factors, coactivators, 
H
istone deacetylase 4 (HDAC4) regulates numer-
ous gene expression programs through its signal-
dependent repression of myocyte enhancer factor 
2 (MEF2) and serum response factor (SRF) transcription 
factors. In cardiomyocytes, calcium/calmodulin-dependent 
protein kinase II (CaMKII) signaling promotes hyper-
trophy and pathological remodeling, at least in part by 
phosphorylating HDAC4, with consequent stimulation of 
MEF2 activity. In this paper, we describe a novel mecha-
nism whereby protein kinase A (PKA) overcomes CaMKII-
mediated activation of MEF2 by regulated proteolysis of 
HDAC4. PKA induces the generation of an N-terminal 
HDAC4 cleavage product (HDAC4-NT). HDAC4-NT se-
lectively inhibits activity of MEF2 but not SRF, thereby 
antagonizing the prohypertrophic actions of CaMKII sig-
naling without affecting cardiomyocyte survival. Thus, 
HDAC4 functions as a molecular nexus for the antagonis-
tic actions of the CaMKII and PKA pathways. These find-
ings have implications for understanding the molecular 
basis of cardioprotection and other cellular processes in 
which CaMKII and PKA exert opposing effects.
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Recently, we and others demonstrated that CaMKII spe-
cifically signals to HDAC4 to promote pathological cardiac 
remodeling (Backs et al., 2006, 2008, 2009; Little et al., 2007; 
McKinsey, 2007; Zhang et al., 2007; Métrich et al., 2010). Here, 
we describe a novel mechanism by which catecholaminergic 
downstream  mediators  regulate  cardiac  transcription  through 
regulated proteolysis of HDAC4. Our findings identify HDAC4   
as a common target of CaMKII and PKA. However, whereas 
CaMKII induces cytosolic accumulation of HDAC4 and de- 
represses HDAC4 target genes, PKA promotes the generation 
of  an  N-terminal  HDAC4 cleavage product (HDAC4-NT), 
which acts as a CaMKII-insensitive repressor that selectively in-
hibits myocyte enhancer factor 2 (MEF2) but not SRF, antagoniz-
ing cardiac remodeling but not affecting cardiomyocyte survival. 
Thus, HDAC4 functions as an integrator of two opposing signal 
transduction pathways that govern cardiac gene expression.
Results
PKA represses MEF2 activity
Signaling by -AR agonists activates CaMKII and other calcium-
dependent protein kinases, which promote MEF2 activity by 
phosphorylating class II HDACs and triggering their export from 
the nucleus. This regulatory mechanism plays a key role in the 
control of cardiac hypertrophy and stress responsiveness of 
cardiomyocytes. Because -AR agonists also activate PKA, we 
sought to determine the potential influence of PKA signaling on 
MEF2 activity. Therefore, we transfected the cardiomyocyte-like 
cell line H9c2 with an MEF2-responsive reporter (3×MEF2-Luc) 
and activated PKA by 1 mM dibutyryl cAMP (dbcAMP). As 
shown in Fig. 1 A, dbcAMP inhibited MEF2 activity, and PKA 
inhibition by KT5720 blunted the repressive effect of dbcAMP.
To further investigate the potential impact of PKA signal-
ing on MEF2 activity and the relationship between PKA and 
and corepressors (Verdin et al., 2003; Haberland et al., 2009). 
The N-terminal regulatory domains of class IIa HDACs contain   
a set of conserved serine residues that control their subcellular 
localization and confer signal responsiveness to downstream 
target genes (Grozinger and Schreiber, 2000; McKinsey et al., 
2000, 2001). Phosphorylation of these serine residues creates 
binding sites for the 14-3-3 chaperone protein, which escorts 
phospho-HDACs from the nucleus to the cytoplasm, allow-
ing the activation of HDAC target genes. Direct oxidation 
also results in accumulation of HDACs in the cytosol (Ago   
et al., 2008).
In the nucleus, HDAC4 functions as a repressor of myo-
cyte enhancer factor-2 (MEF2) and serum response factor (SRF), 
transcription factors that regulate muscle and stress-responsive 
genes as well as genes that maintain cardiomyocyte integrity 
(Edmondson et al., 1994; Naya et al., 1999; Passier et al., 2000; 
Niu et al., 2005; Paroni et al., 2007). Interaction of MEF2 or 
SRF  with  class  II  HDACs  silences  the  expression  of  target 
genes of these transcription factors (Miska et al., 1999; Paroni 
et al., 2007). Mice lacking MEF2D, the predominant MEF2 iso-
form in the adult heart, display normal cardiac function but are 
protected against stress-induced cardiac remodeling (Kim et al., 
2008). In contrast, SRF is crucial for cardiac function, such that 
its deletion results in cardiomyopathy (Parlakian et al., 2005). 
How HDAC4 discriminates between MEF2 and SRF in differ-
ent settings is unclear. Gene deletion studies in mice revealed 
that class IIa HDACs are key regulators of tissue growth and 
development (Haberland et al., 2009). HDAC5 and HDAC9 re-
press cardiomyocyte hypertrophy (Zhang et al., 2002; Chang 
et al., 2004), HDAC4 represses chondrocyte hypertrophy (Vega 
et al., 2004), and HDAC7 regulates vascular integrity (Chang et al., 
2006). Mice lacking HDAC4 die perinatally as a result of pre-
mature ossification, which prevented us from studying the po-
tential role of HDAC4 in adult hearts.
Figure 1.  PKA represses MEF2 activity. (A) H9c2 myocytes were 
transfected  with  the  3×MEF2-Luc  reporter  and  stimulated  with   
1 mM dbcAMP in the absence or presence of the PKA inhibitor 
KT5720 (2 µM). Firefly luciferase was normalized to renilla lu-
ciferase expression (driven by a cytomegalovirus promoter). The 
experiment was performed in triplicates. Similar results were ob-
tained in three different experiments. (B) COS cells were trans-
fected  with  the  3×MEF-Luc  reporter  and  expression  plasmids 
encoding 100 ng MEF2C, 10 ng FLAG-HDAC4, and 100 ng 
CaMKII in the absence and presence of low (25 ng) or high (50 ng) 
amounts of Myc-PKA expression plasmid, as indicated. Firefly 
luciferase was normalized to renilla luciferase expression. West-
ern blots showing expression of MEF2C, FLAG-HDAC4, CaMKII, 
and Myc-PKA in the same sample as used for the reporter assay 
are shown below the reporter assay quantification. IB, immuno-
blot. Molecular mass is indicated in kilodaltons. The experiment 
was performed in duplicates. Similar results were obtained in 
three different experiments. (A and B) Error bars indicate ± SEM. 
(C) A model showing antagonistic effects of PKA and CaMKII on 
HDAC4 and MEF2 activity.405 PKA signaling to HDAC4 • Backs et al.
CaMKII signaling, we tested the effects of these kinases on 
MEF2 in the presence of HDAC4 in transfected COS cells. As 
previously reported (Backs et al., 2006), CaMKII signaling 
relieved MEF2C from repression by HDAC4 (Fig. 1 B). Strik-
ingly, PKA dose dependently overcame the stimulatory effect 
of CaMKII on MEF2 activity, suggesting that the PKA and 
CaMKII signaling pathways act in an opposing manner to mod-
ulate the MEF2-HDAC4 axis (Fig. 1 C).
PKA-dependent proteolytic processing  
of HDAC4
CaMKII phosphorylates three sites in the N-terminal regula-
tory domains of HDAC4 and other class IIa HDACs, creating 
binding sites for 14-3-3 chaperone protein, which mediates 
nuclear export (Backs et al., 2006). To begin to explore the 
mechanistic basis of the inhibitory effect of PKA on MEF2, 
we  investigated  whether  PKA  altered  14-3-3  binding  to 
HDAC4 and the closely related HDAC5, 7, and 9 (Fig. 2 A). 
Unlike CaMKII, the catalytic subunit of PKA did not increase 
14-3-3 binding to these HDACs. Strikingly, however, we ob-
served an N-terminal fragment of HDAC4 of 28 kD when 
coexpressed with PKA. We refer to this HDAC4 cleavage 
product as HDAC4-NT. HDAC4-NT production was highly 
reproducible and was confirmed by antibodies directed against 
the N terminus of HDAC4, such as anti–HDAC4 N-18 (Santa 
Cruz Biotechnology, Inc.). Occasionally, we detected another 
peptide of higher molecular mass, but this was also seen with-
out  kinase  coexpression.  We  also  tested  whether  CaMKII 
could induce limited proteolysis of HDAC4 or HDAC5, but 
no N-terminal cleavage products were observed (Fig. S1 A). 
In contrast to HDAC4-NT, no C-terminal cleavage product 
was detected with a C-terminal HDAC4-Myc tag, suggesting 
that the C-terminal part of HDAC4 was unstable (Fig. S1 B)
Next, we tested whether endogenous HDAC4 was proteo-
lytically processed in response to -AR–dependent PKA activa-
tion in vivo. We treated wild-type (WT) mice and mice lacking 
the catalytic  subunit of PKA (Skålhegg et al., 2002), the major 
PKA catalytic isoform in the heart, with four sequential injections 
of the adrenergic agonist isoproterenol (Iso) over a period of 4 h 
(60 µg/g in total). Western blot analysis of cardiac extracts using 
an antibody to the N terminus of HDAC4 detected a basal level of 
HDAC4-NT under control conditions and a pronounced increase 
after Iso treatment (Fig. 2 B). The appearance of HDAC4-NT in 
response to Iso treatment was accompanied by a decrease in full-
length  (FL)  HDAC4  protein.  In  PKA-null  mice,  Iso-induced 
HDAC4-NT was markedly diminished, confirming that PKA is 
Figure  2.  PKA-dependent  proteolysis  of  HDAC4.  (A)  Coimmunopre-
cipitation assay with lysates from COS cells expressing FLAG-HDAC4, 
-HDAC5, -HDAC7, and -HDAC9 (MEF2-interacting transcription repres-
sor). Extracts were immunoprecipitated (IP) with anti-FLAG antibody and 
immunoblotted (IB) with an antibody directed against endogenous 14-3-3 
protein (top). The effect of Myc-PKA was tested. Input proteins were de-
tected with antibodies directed against FLAG and Myc, identifying an 
N-terminal FLAG-HDAC4 cleavage product (NT) of 28 kD. (B) Western 
blot analysis of cardiac extracts from WT and Prkaca knockout (PKA
/) 
mice that were treated for 4 h with or without Iso (60-µg/g body weight,   
15 µg/g per hour). The membrane was analyzed with an antibody 
directed against the N terminus of HDAC4 (N-18). Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was detected as a loading control. 
(C and D) COS cells were transfected with FLAG-HDAC4 and Myc-PKA. 
HDAC4-FL and -NT were detected by Western blot analysis using an anti-
body directed against FLAG. The effects of inhibitors of calpains (5 and 
20 µM MDL28170 and 50 µM EST), the proteasome (10 and 25 µM 
MG132), cysteine proteases (10 µM E64 and 100 µM leupeptin), aspar-
tic proteases (10 µM pepstatin A), and serine proteases (100 and 400 µM 
AEBSF) on HDAC4-NT production (C) and different treatment periods of 
AEBSF to determine the half-life of posttranslationally produced HDAC4-
NT (D) are shown. Molecular mass is indicated in kilodaltons.
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protein has been reported to display a half-life of 8 h (Liu et al., 
2004). To examine the stability of HDAC4-NT, we treated COS 
cells, in which HDAC4-NT was already produced, with an ef-
fective dose of AEBSF and found that HDAC4-NT disappeared 
with a half-life of 2 h (Fig. 2 D).
To verify whether HDAC4 is cleaved in the cytosol or the 
nucleus, we used two mutants that show mutually exclusive 
localization to these compartments. Cytosolic HDAC4, in which 
the NLS (amino acids 247–289) was deleted (HDAC4 NLS), 
was cleaved to the same degree as a nonphosphorylatable nu-
clear HDAC4 mutant (HDAC4–Ser-246/467-Ala [2×S/A]) in 
not only sufficient but also necessary for HDAC4-NT production 
in response to adrenergic activation of PKA signaling.
We attempted to characterize the PKA-dependent HDAC4 
protease using a series of protease inhibitors. AEBSF, a serine 
protease inhibitor, prevented PKA-mediated HDAC4 cleavage, 
whereas inhibitors of calpain, caspases, the proteasome, cysteine 
proteases, and aspartic proteases had no effect on HDAC4-NT 
production (Figs. 2 C and S1 C). AEBSF inhibits a broad range 
of serine proteases and typically exerts cytotoxic effects at concen-
trations >400 µM. AEBSF effectively inhibited HDAC4-NT pro-
duction at a concentration of 250 µM (Fig. S1 D). The FL HDAC4 
Figure 3.  Identification of the HDAC4 cleavage site. (A) A schematic of the HDAC4 protein and the amino acid sequence surrounding Tyr201. The 
sequence of this HDAC4 domain is aligned with other HDACs. The cleavage site lies 15 amino acids after the MEF2-binding domain in a unique region 
of HDAC4. Conserved amino acids are highlighted in blue. (B and C) Western blot analysis of lysates from COS cells expressing FLAG-HDAC4-WT and 
different FLAG-HDAC4 mutants (as indicated) together with Myc-PKA. HDAC4-FL and -NT expression was detected with an antibody directed against FLAG 
and PKA expression with an antibody directed against Myc. Mutants that fail to be cleaved are boxed in red. IB, immunoblot. (D) An anti-FLAG immunopre-
cipitate (IP) of lysates of COS cells that expressed 3×FLAG-HDAC4 with and without PKA was analyzed by SDS-PAGE and Coomassie staining. HDAC4-NT 
(marked with an asterisk in the PKA lane) was identified based on its sole production in the presence of PKA. This band was excised from the gel, and tryptic 
peptides were analyzed. (E and F) MS analysis of the most C-terminal peptide obtained by tryptic digestion of immunoprecipitated HDAC4-NT (R200L) is 
shown (E). All HDAC4 peptides that were identified are marked in red (F). Molecular mass is indicated in kilodaltons.407 PKA signaling to HDAC4 • Backs et al.
that amino acids 202 and 203 were essential for the cleavage 
event (Fig. 3 B). We also mutated amino acids 201 and 204 to 
residues with distinct biochemical properties and found that 
Gly204, when mutated to a proline but not to an alanine, pre-
vented cleavage (Fig. 3 C).
To identify the exact HDAC4 cleavage site, we immuno-
precipitated and purified N-terminally 3×FLAG-tagged HDAC4 
from an anti-FLAG affinity column and eluted it with 3×FLAG 
competitor peptide. For this experiment, we used the HDAC4 
R200L mutant that was as efficiently cleaved as WT HDAC4. 
which Ser246 and Ser467 were replaced by an alanine, imply-
ing that cleavage occurs in both compartments (Fig. S1 E).
Identification of the HDAC4 cleavage site
The structure of HDAC4 is schematized in Fig. 3 A. To pin-
point  the  cleavage  site,  we  generated  deletion  mutants  of 
HDAC4. HDAC4 186–220 and 186–205 were resistant to 
PKA-mediated cleavage, suggesting that the cleavage site lies 
between amino acids 186 and 205. We then mutated each indi-
vidual amino acid between amino acids 188 and 205 and found 
Figure 4.  Identification of a PKA-binding domain on HDAC4. (A and B) FLAG-HDAC4, -HDAC5, and -HDAC4/5 chimeric proteins (as indicated in B) were 
expressed in COS cells in the presence and absence of Myc-PKA. Expression of FLAG-tagged HDAC4-FL and -NT was detected by Western blot analysis 
using an antibody directed against FLAG. The schematic (B) summarizes the WT and mutant HDACs that were cleaved. IB, immunoblot. (C and D) Muta-
tional analysis of a unique domain of HDAC4. As indicated in D, PKA was expressed with HDAC4 mutants, in which this domain was deleted or single 
amino acids were replaced by an alanine. HDAC4-FL and -NT production were detected by Western blot analysis. The amino acids of HDAC4 that were 
found to be required for HDAC4-NT production are framed in red, and conserved amino acids are highlighted by black (identical residues) and gray (simi-
lar residues) boxes (C). (E) Summary of essential amino acids within the central part of HDAC4 required for HDAC4-NT production. The region between 
amino acid 639 and 644 is required for PKA responsiveness. (F) Coimmunoprecipitation assay with lysates from COS cells expressing FLAG-HDAC4, the 
indicated FLAG-HDAC4 mutants, and Myc-PKA. Extracts were immunoprecipitated with anti-FLAG antibody and blotted with an antibody directed against 
Myc. Input proteins were detected with antibodies directed against FLAG and Myc. These data show that Ser633 and Ser642 are required not only for 
HDAC4-NT production but also for PKA binding. As a control, mutation of the cleavage site (W202A) prevented only HDAC4-NT production but not PKA 
binding. Molecular mass is indicated in kilodaltons.JCB • VOLUME 195 • NUMBER 3 • 2011   408
HDAC4 fusion protein to accumulate in the cytosol, where it 
stained the cytosol yellow. Nuclear localization of RFP-HDAC4-
GFP was only very slightly increased when coexpressed with 
PKA alone. Strikingly, however, in cells coexpressing CaMKII, 
PKA, and RFP-HDAC4-GFP, 20% of the nuclei were red, 
suggesting that HDAC4 was proteolytically processed and that 
HDAC4-NT accumulated in the nucleus, where it could act as a 
transcriptional regulator (Fig. 5 B).
HDAC4-NT selectively represses MEF2
Intriguingly, HDAC4-NT contains the MEF2-binding domain 
(Fig. 3 A). Thus, we tested whether PKA promoted the associa-
tion of HDAC4-NT with MEF2. Indeed, HDAC4-NT in a lysate 
of  PKA  and  HDAC4-FL–expressing  cells  was  pulled  down 
with a GST-MEF2C fusion protein (Fig. 6 A). Similarly, Myc-
MEF2C  coimmunoprecipitated  with  FLAG-HDAC4  2–201 
(NT) (Fig. 6 B). These findings suggested two interesting possi-
bilities: HDAC4-NT might function as a repressor of MEF2 or 
as  a  competitor  with  HDAC4-FL  or  other  class  II  HDACs, 
thereby enhancing MEF2 activity. To test these possibilities, 
we examined whether HDAC4 2–201 (NT) was able to inter-
fere with the activation of an MEF2-dependent luciferase re-
porter (3×MEF2-Luc). As shown in Fig. 6 C, HDAC4-NT was 
By  using  this  mutant,  we  could  detect  protein  fragments 
around amino acids 200–203. Only when coexpressed with 
PKA did we observe a Coomassie blue–stained band of 28 kD 
after  SDS-PAGE  (Fig.  3  D).  Tryptic  digestion  and  mass 
spectrometry (MS) of this band identified a peptide ending at 
amino acid 201 (Fig. 3, E and F). MS of the corresponding re-
gion of the control lane lacking PKA yielded no HDAC4 pep-
tides. Based on the mutational analysis in combination with the 
results of MS, we conclude that the amino acid boundary be-
tween Tyr201 and Trp202 defines the PKA-mediated cleavage 
site of HDAC4, with Trp202, Tyr203, and Gly204 being critical 
for proteolysis.
Mapping of a critical PKA-binding site  
on HDAC4
To begin to map the domain of HDAC4 that conferred respon-
siveness to PKA and consequent proteolytic cleavage, we cre-
ated a series of HDAC4/HDAC5 chimeric proteins (Fig. 4, A 
and  B).  Only  those  chimeric  proteins  containing  portions  of 
HDAC4 from amino acid 143 to 780 were able to give rise to 
HDAC4-NT in response to PKA. Thus, besides the actual cleav-
age site after Tyr201, other domains within this region must be 
crucial for HDAC4-NT production. Sequence comparison re-
vealed that a region before amino acid 780 contains a poly-
peptide sequence (amino acids 636–651) that is present only in 
HDAC4 and not in other class IIa HDACs (Fig. 4 C). Deletion 
of this sequence or mutation of key residues (HDAC4 639–644 
FPVSVQ) within this region prevented HDAC4-NT production 
in response to PKA (Fig. 4, D and E). We also tested other amino 
acids around this region and found that Ser633, which lies adja-
cent to a CaMKII phosphorylation site (Ser632), was required 
for the PKA effect. Although neither Ser633 nor Ser642 matches 
the perfect PKA phosphorylation consensus site (RRXSY, with 
Y being the hydrophobic residue), we performed a series of 
kinase assays with recombinant GST-HDAC4 fusion proteins 
(HDAC4 419–739), but we were unable to detect specific phos-
phorylation  events  of  these  sites.  It  is  possible  that  efficient 
phosphorylation requires folding events of HDAC4 including 
N-terminal regions not present in the GST-HDAC4 419–739 
fusion protein. However, we found that PKA interacts directly 
with FL HDAC4 and that the two mutations that prevent PKA-
dependent cleavage of HDAC4 markedly diminished the ability 
of HDAC4 to bind PKA (Fig. 4 F). Thus, we conclude that PKA 
binding to the central region of HDAC4 renders the N-terminal 
domain of HDAC4 sensitive to proteolysis. A kinase-dead mutant 
of PKA (PKA K72H) failed to induce HDAC4-NT production, 
implying that the PKA requires enzymatic activity (Fig. S2). 
Because we were unable to identify PKA phosphorylation sites 
on  HDAC4  that  mediate  proteolysis,  we  speculate  that  the 
HDAC protease may need to be activated by PKA to enable it to 
cleave HDAC4.
HDAC4-NT localizes to the nucleus
To further determine the subcellular localization of HDAC4-
NT, we fused the dsRed monomer fluorescent protein RFP to 
the N terminus and the EGFP to the C terminus of HDAC4 
(Fig. 5 A). Coexpression with CaMKII in COS cells forced the 
Figure  5.  HDAC4-NT  localizes  to  the  nucleus.  (A)  RFP-HDAC4-GFP 
was coexpressed with CaMKII, PKA, or both in COS cells. A schematic 
of  the  RFP-HDAC4-GFP  fusion  is  shown.  (B)  Subcellular  localization  of 
RFP-HDAC4-GFP in the green and red fluorescence channels is shown. 
To  assess  localization  of  HDAC4-FL  versus  HDAC4-NT,  both  channels 
were merged, identifying red nuclei as a sign for nuclear accumulation 
of HDAC4-NT. Nuclei are visualized by DAPI staining. The quantitative 
analysis is shown below the representative images. More than 100 cells 
per condition were analyzed in three selected fields. The ratio per field was 
quantified (n = 3). Bar, 25 µm.409 PKA signaling to HDAC4 • Backs et al.
Figure 6.  MEF2-selective effects of HDAC4-NT in cardiomyocytes. (A) A pull-down assay with GST or GST-MEF2C and a lysate of COS cells expressing 
FLAG-HDAC4 and PKA. An anti-FLAG Western blot analysis of the COS cell lysate input and the pull-down experiment is shown. IB, immunoblot. (B) Co-
immunoprecipitation assay with lysates from COS cells coexpressing FLAG-tagged HDAC4-FL (in the absence and presence of PKA) or HDAC4-NT and Myc-
MEF2C. The immunoprecipitate (IP) was analyzed with an antibody directed against Myc. Input proteins were detected with antibodies directed against 
FLAG and Myc. These data show that both HDAC4-FL and -NT bind to MEF2C. (C) COS cells were transfected with the 3×MEF-Luc reporter and expres-
sion plasmids encoding MEF2C and FLAG-tagged HDAC4-FL, HDAC4-NT, or HDAC5, as indicated. Firefly luciferase activity was normalized to renilla 
luciferase expression (driven by a cytomegalovirus promoter). Western blots showing expression of FLAG-HDACs and MEF2C in the same sample used for 
reporter assay are shown below the reporter assay quantification. (D) Coimmunoprecipitation assay with lysates from COS cells expressing FLAG-tagged 
HDAC4-FL, HDAC4 2–289, and HDAC4 2–201 (NT) together with SRF. The FLAG immunoprecipitate was blotted with an antibody directed against SRF. 
Input proteins were detected with antibodies directed against SRF and FLAG. These data show that HDAC4-FL and HDAC4 2–289 bind strongly to SRF, 
but HDAC4 2–201 (NT) does not. (E and F) COS cells were cotransfected with the 4×CARG-Luc reporter and expression plasmids encoding SRF and 
FLAG-tagged HDAC4-FL, HDAC4-NT (2–201), HDAC5, or HDAC4 2–289, as indicated. Western blots showing expression of FLAG-HDACs and SRF in 
the same sample used for reporter assay are shown below the reporter assay quantification. Molecular mass is indicated in kilodaltons. (C, E, and F) The 
experiments were performed in duplicates. Similar results were obtained in three different experiments. (G) A schematic showing the selective interaction 
and repression of MEF2 by HDAC4-NT.JCB • VOLUME 195 • NUMBER 3 • 2011   410
Figure 7.  HDAC4-NT affects cardiomyocyte hypertrophy but not viability. (A) A luciferase reporter assay in NRVMs that were transduced with adeno-
viruses (Ad) for 3×MEF2-Luc and HDAC4-FL and mutants, as indicated. Ad–3×MEF2-Luc was cotransduced with adenoviruses encoding the indicated forms 
of HDAC4 in the presence of 100 nM ET-1. Firefly luciferase expression was normalized to the protein content of each sample. HDAC expression in the 
same preparation as used for reporter assays was detected using an antibody directed against the N terminus of HDAC4 (N-18) and is shown below 
the reporter assay quantification. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IB, immunoblot. Molecular mass is indicated in kilodaltons. (B) Immuno-
cytochemistry of NRVMs transduced with Ad–HDAC4-FL, -S/A, 2–201 (NT), or 2–289 using antibodies recognizing sarcomeric -actinin (red; top) 
to assess myocyte size and sarcomere organization and FLAG (green; bottom) to determine the subcellular localization of HDAC4-FL and mutants. DAPI 
staining was used to label nuclei. NRVMs are shown under baseline conditions or after treatment with 100 nM ET-1, as indicated. Quantitative analysis 411 PKA signaling to HDAC4 • Backs et al.
2–201 (NT) and 2–289 did not perturb myocyte structure but 
inhibited cardiomyocyte hypertrophy by 50%. TUNEL and 
annexin V/propidium iodide (PI) assays revealed that HDAC4-
S/A, -FL, and 2–289 induced apoptotic cell death, but HDAC4 
2–201 (NT) did not (Fig. 7, C and D). This observation is con-
sistent with the proapoptotic effects of caspase 3, which medi-
ates the production of HDAC4 2–289. Collectively, these data 
imply that HDAC4-NT (2–201) selectively antagonizes MEF2-
dependent cardiomyocyte remodeling and hypertrophy but main-
tains SRF-mediated myocyte viability.
Discussion
Our results identify HDAC4 as a bipolar integrator of PKA and 
CaMKII signaling, which impose antagonistic influences on car-
diac gene expression (Fig. 8). Whereas CaMKII forces HDAC4 
to accumulate in the cytosol, thereby activating MEF2 target 
genes, PKA triggers proteolytic cleavage of HDAC4, generating 
a signal-insensitive repressor of MEF2 but not SRF. The differ-
ential regulation of HDAC4 function via PKA and CaMKII has 
implications for many physiological and pathophysiological pro-
cesses in which PKA and CaMKII are differentially regulated.
Control of HDAC4 targets by opposing 
kinase pathways
It has been well established that the distribution of class II 
HDACs between the nucleus and cytoplasm depends on the sta-
tus of phosphorylation of three serine residues in the N-terminal 
regulatory domains of these HDACs, which serve as binding 
sites for 14-3-3 proteins (Verdin et al., 2003; Backs and Olson, 
2006; McKinsey, 2007; Haberland et al., 2009). Dephosphory-
lation of these sites by PP2A antagonizes CaMK signaling, pro-
moting nuclear retention of class II HDACs (Sucharov et al., 
2006; Illi et al., 2008; Paroni et al., 2008). We propose that 
PKA-mediated proteolytic processing of HDAC4 results in a 
similar effect. However, proteolytic control of HDAC4 is dis-
tinct in two important respects. First, HDAC4-NT resists opposing 
kinase signaling (e.g., by CaMKII or PKD) and persistently re-
presses MEF2 gene programs. In contrast, dephosphorylation is 
a transient mechanism, continually counteracted by phosphory-
lation. Second, HDAC4-NT provides another layer of transcrip-
tion factor specificity because it represses MEF2 more efficiently 
than SRF. This is in contrast to HDAC4-FL and to caspase-
processed HDAC4 (HDAC4 1–289). Moreover, HDAC4-NT 
would not be predicted to affect the activity of nuclear factor of 
activated T-cells (NFAT), which binds indirectly via the DnaJ-
related factor Mrj to the C-terminal half of HDAC4 (Dai et al., 
2005). The regulated proteolysis of HDAC4 therefore allows 
almost as efficient as HDAC4-FL or HDAC5-FL in repressing 
MEF2 reporter activity.
In addition to inhibiting MEF2, HDAC4 represses SRF-
dependent transcription (Davis et al., 2003). Moreover, pro-
teolytic cleavage of HDAC4 at Asp289 is mediated by caspases 
(Liu et al., 2004; Paroni et al., 2004), and HDAC4 2–289 dis-
played an increased affinity to SRF (Paroni et al., 2007). How-
ever,  to  our  knowledge,  the  exact  SRF-binding  domain  of 
HDAC4 was not mapped. In coimmunoprecipitation assays, 
we found that HDAC4 2–289 bound stronger to SRF than 
HDAC4 2–201 (NT) (Fig. 6 D), suggesting that the region 
between 201 and 289 contains a critical part of the SRF-binding 
domain. Likewise, HDAC4 2–201 (NT) was a relatively ineffi-
cient repressor of SRF activity, comparable with the mild re-
pressive  function  of  HDAC5  (Fig.  6  E).  Therefore,  we 
compared the repressive potential of HDAC4 2–201 (NT) and 
2–289 on MEF2 and SRF reporters. Whereas the longer frag-
ment inhibited both reporters efficiently, the effect of HDAC4 
2–201 (NT) on SRF activity was weaker, implying that PKA-
dependent proteolytic processing of HDAC4 results in differential 
regulation of target transcription factors favoring repression 
of MEF2 (Fig. 6 G).
MEF2-selective effects of HDAC4-NT  
in cardiomyocytes
Next, we investigated the effects of HDAC4-NT on neonatal rat 
ventricular myocytes (NRVMs). First, we activated MEF2 by 
endothelin-1 (ET1), a potent hypertrophic agonist that drives 
nuclear export of class II HDACs (McKinsey, 2007). Despite 
similar expression levels, HDAC4-FL (WT protein) was less 
efficient in repressing ET1-induced MEF2 activity as compared 
with HDAC4 2–201 (NT) and 2–289 (Fig. 7 A), confirming that 
the  proteolytic  fragments  are  insensitive  to  kinases  such  as 
CaMKII and PKD, which induce nucleocytoplasmic shuttling 
of HDAC4-FL. As expected, HDAC4-S/A, a mutant of HDAC4 
lacking the three CaMKII/PKD phosphorylation sites, strongly 
repressed ET1-induced MEF2 activity. Immunocytochemistry 
of NRVMs showed nuclear localization of HDAC4-S/A, 2–201 
(NT), and 2–289 under baseline conditions but also upon stimu-
lation with ET1, confirming the insensitivity of these HDAC4 
mutants to upstream kinases (Fig. 7 B). In contrast, HDAC4-FL 
responded to ET1 signaling and translocated to the cytosol, 
which is consistent with its effect on MEF2 activity after ET1 
stimulation. Sarcomeric -actinin staining demonstrated that 
HDAC4-S/A was the strongest repressor of cardiomyocyte size. 
However, HDAC4-S/A also perturbed myocyte structure. Con-
sistent with its maintained signal responsiveness, HDAC4-FL 
reduced cardiomyocyte hypertrophy by only 10–20%. HDAC4 
of cardiomyocyte hypertrophy is shown on the right. 51–100 NRVMs were analyzed per condition (n > 50). *, P < 0.05 versus control. Bar, 50 µm.   
(C) TUNEL assays of NRVMs transduced with Ad–HDAC4-WT, -S/A, 2–201 (NT), or 2–289. Apoptotic nuclei appear in green, and NRVMs were counter-
stained for sarcomeric -actinin. Nontransduced NRVMs (control) serve as a negative control, and adriamycin-treated NRVMs serve as a positive control. 
Quantitative analysis of apoptotic nuclei per NRVMs is shown on the right. More than 55 NRVMs per condition were analyzed in four to eight selected 
fields. The percentage in each field was quantified (n ≥ 4). *, P < 0.05 versus control. Bar, 200 µm. (D) Annexin V–FITC/PI staining of NRVMs. NRVMs 
were nontreated (control), treated with adriamycin (positive control), or transduced with Ad–HDAC4-FL, -S/A, 2–201 (NT), or 2–289. Quantitative analysis 
of annexin V and PI-positive cells per total cell number is shown on the right. 59–144 cells were analyzed per condition in three to five selected fields. The 
percentage in each field was quantified (n ≥ 3). *, P < 0.05 versus control. Bar, 100 µm.
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-AR stimulation would generate low levels of HDAC4-NT 
and would translocate the noncleaved HDAC4 to the cytosol. 
Therefore, HDAC4 represents a transcriptional checkpoint in 
-AR signaling, and the balance between PKA and CaMKII 
activation  dictates  the  consequences  on  HDAC4-dependent 
transcription (Fig. 8).
Physiological implications
We speculate that the mechanistic findings of this study explain 
why repetitive transient elevations of catecholamines—as occur 
during interval exercise training—would not result in activation 
of MEF2 target genes. In such settings, HDAC4-NT would be 
expected to protect the myocardium against the expression of 
such genes in response to physiological stress conditions. Addi-
tionally, the short half-life of HDAC4-NT of 2–3 h (as com-
pared with 8 h of HDAC4-FL) would be ideal to bridge such 
stress situations. During chronic heart failure, CaMKII is typi-
cally activated (Wang et al., 2004; Grimm and Brown, 2010), 
which would result in the cytosolic accumulation of HDAC4-
FL (Backs et al., 2006, 2009). We propose that under such con-
ditions, moderate levels of HDAC4-NT are cardioprotective 
and that the success of -blocker therapy in heart failure might 
be explained, at least in part, by its ability to prevent -AR 
desensitization, resulting in higher levels of the HDAC4-NT 
production in response to -AR stimulation.
It has been suggested that accumulation of HDAC4 in the 
nucleus may cause cell death in neurons (Bolger and Yao, 2005). 
Likewise, SRF has been shown to be crucial for cardiac integ-
rity, function, and viability (Parlakian et al., 2005). Thus, in con-
trast to caspase activation, PKA-mediated proteolysis of HDAC4 
may circumvent cell death events as a result of the inability of 
HDAC4-NT to efficiently repress SRF. Further studies need to 
clarify whether HDAC4-NT production in certain pathophysio-
logical conditions such as myocardial infarction would be mal-
adaptive or, as proposed here, might even be cardioprotective.
Calcium-dependent signaling via CaMKII and cAMP sig-
naling via PKA play opposing roles in many cellular processes such   
as chondrocyte differentiation, in which parathyroid hormone- 
related peptide signaling through PKA keeps chondrocytes 
in an undifferentiated status, but, noncanonical Wnt signaling, 
which activates CaMKII, promotes chondrocyte hypertrophy 
and ossification (Li et al., 2011). Likewise, oocytes are kept in 
a state of cell cycle arrest by cAMP, whereas CaMKII- in-
duces cell cycle resumption (Backs et al., 2010). HDAC4 is 
highly expressed both in chondrocytes (Vega et al., 2004) and 
oocytes (Kageyama et al., 2006). Thus, it will be of interest to 
investigate the role of HDAC-NT production in these and other 
cell types.
Targets for pharmacological modulation of 
the HDAC4-MEF2 pathway
In the future, it will be of interest to determine HDAC4-NT 
levels in different tissues and during different states of cardio-
vascular diseases. The PKA-dependent HDAC4 protease also 
represents an interesting therapeutic target. In this study, we 
attempted to define the nature of the protease by chemical   
inhibitors. Only serine protease inhibitors were able to prevent 
PKA to selectively repress MEF2 but not SRF or NFAT targets. 
This is of functional importance because accumulation of both 
HDAC4-FL and caspase-processed HDAC4 have been shown 
to induce apoptosis (Paroni et al., 2007), whereas we show here 
that HDAC4-NT does not efficiently induce apoptosis. Thus, 
PKA-dependent proteolysis of HDAC4 represents a mechanism 
of selective cardioprotection against MEF2 target gene activa-
tion (Kim et al., 2008).
CaMKII signals selectively to HDAC4 by docking to a 
domain that is uniquely present in HDAC4 but not in other class 
IIa HDACs (Backs et al., 2006). Remarkably, we show here 
that PKA also selectively signals to HDAC4 by docking to   
another unique domain that actually lies in close proximity to 
the CaMKII docking site. Why do two downstream kinases in   
-AR signaling pathways target the same HDAC and exert oppos-
ing functions on HDAC4-dependent cardiac transcription? The 
answer to this question might lie in the different time courses of 
PKA versus CaMKII activation. Acute -AR stimulation acti-
vates PKA, but sustained stimulation of -ARs leads to an un-
coupling of adenylyl cyclase from -ARs, resulting in decreased 
cAMP levels and PKA inactivation (Grimm and Brown, 2010). 
Moreover, sustained -AR stimulation, by mechanisms that 
are poorly understood, leads to progressive PKA-independent 
CaMKII activation (Zhu et al., 2003; Wang et al., 2004; Grimm 
and Brown, 2010). Thus, whereas acute -AR stimulation would 
generate high levels of the HDAC4-NT fragment, sustained 
Figure 8.  PKA-dependent proteolysis of HDAC4 overcomes CaMKII- 
mediated MEF2 activation. (A) A schematic of HDAC4 highlighting its 
domains involved in CaMKII and PKA signaling as well as MEF2 and SRF 
repression. P, phosphorylated serine. (B) Chronic -adrenergic stimulation 
leads, via calcium-dependent mechanisms, to CaMKII activation, which 
mediates cytosolic accumulation of HDAC4 and activation of MEF2- and 
SRF-dependent gene programs. In contrast, acute adrenergic stimulation 
leads to cAMP-dependent PKA activation, which mediates proteolytic pro-
cessing of HDAC4 to HDAC4-NT. HDAC4-NT acts as a CaMKII-insensitive 
repressor of MEF2 but not SRF.413 PKA signaling to HDAC4 • Backs et al.
Indirect immunofluorescence
COS cells were grown on glass coverslips, fixed in 4% PFA, permeabil-
ized in 0.1% Triton X-100, and blocked in PBS containing 5% goat serum. 
A primary antibody against FLAG (monoclonal or rabbit; Sigma-Aldrich) 
was used at a dilution of 1:200. Secondary antibodies conjugated to either 
fluorescein or Texas red (Vector Laboratories) were also used at a dilution 
of 1:200. NRVMs were stained with antibodies directed against sarco-
meric -actinin (Sigma-Aldrich). All images were captured at a magnifica-
tion of ×40.
Apoptosis assays
TUNEL assays were performed using the in situ cell death detection kit 
(Roche) according to the manufacturer’s protocol. To quantify the number 
of apoptotic NRVMs, NRVMs were counterstained with sarcomeric -actinin, 
and the total numbers of NRVMs and TUNEL-positive nuclei were counted 
in 10 low power fields in three independent experiments. For each experi-
mental condition, contiguous visual fields were counted to accumulate 
data on 100 NRVMs per condition per experiment. For annexin V and 
PI staining, NRVMs were labeled with annexin V–FITC and PI. Approxi-
mately 100 cells were counted per condition in more than three randomly 
selected fields. Stained cells were normalized to total cell count as judged 
by DAPI staining. More than 80% of cells were sarcomeric -actinin posi-
tive. Adriamyicn treatment (1 µM for 6 h) was used as a positive control.
Coimmunoprecipitation and immunoblotting
COS and cells and NRVMs were harvested 1 d after transfection or trans-
duction in 50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, and 1% Tri-
ton X-100 supplemented with protease inhibitors (Complete; Roche) and   
1  mM  PMSF.  FLAG-tagged  proteins  were  immunoprecipitated  with  M2- 
agarose conjugate (Sigma-Aldrich) and thoroughly washed with lysis buffer. 
Bound proteins were resolved by SDS-PAGE, transferred to PVDF mem-
branes, and immunoblotted as indicated with either anti-Myc antibody 
(polyclonal, A-14; Santa Cruz Biotechnology, Inc.), a monoclonal anti-
FLAG antibody (M2; Sigma-Aldrich), or a polyclonal anti-14-3-3 antibody 
(Abcam). HDAC4-NT generated from endogenous HDAC was detected 
with anti-HDAC4 (polyclonal, N-18). MEF2, SRF, and CaMKII antibodies 
were obtained from Santa Cruz Biotechnology, Inc. A monoclonal glycer-
aldehyde 3-phosphate dehydrogenase antibody (Millipore) was used as a 
loading control.
Reporter assays
COS  cells  were  transiently  transfected  with  vectors  for  CaMKII,  PKA, 
MEF2C, and a luciferase reporter gene under the control of three copies of 
an  MEF2-binding  site  (3×MEF2-Luc)  or  four  copies  of  CARG  boxes 
(4×CARG-Luc). H9c2 cells were transiently transfected with 3×MEF2-Luc, 
and NRVMs were transduced with Ad–3×MEF2-Luc to detect endogenous 
MEF2 activity. 24 h after transfection, cells were harvested, and luciferase 
and -galactosidase levels were determined.
In-gel tryptic digestion and liquid chromatography tandem  
MS (MS/MS) analysis
Protein bands were cut from the gel out with a scalpel and reduced, alkyl-
ated, and digested with trypsin (Catrein et al., 2005) using a liquid han-
dling system (DigestPro MS; intavis AG). Peptides were extracted from the 
gel pieces with 50% acetonitrile/0.1% trifluoroacetic acid, concentrated 
nearly to dryness in a SpeedVac vacuum centrifuge (Concentrator 5301; 
Eppendorf International), and diluted to a total volume of 30 µl with 0.1% 
trifluoroacetic acid. 25 µl of the sample was analyzed by a nanoHPLC sys-
tem (Eksigent) coupled to an electrospray ionization mass spectrometer 
(LTQ Orbitrap; Thermo Fisher Scientific). The sample was loaded on a C18 
trapping column (Inertsil; LC Packings) with a flow rate of 10 µl/min of 
0.1% trifluoroacetic acid. Peptides were eluted and separated on an ana-
lytical column (75 µm × 150 mm) packed with 3 µm of C18 material (Inert-
sil) with a flow rate of 200 nl/min in a gradient of buffer A (0.1% formic 
acid) and buffer B (0.1% formic acid and acetonitrile) for the following: 
0–6 min in 3% buffer B, 6–60 min in 3–40% buffer B, and 60–65 min in 
60–90% buffer B. The column was connected with a nanoelectrospray 
ionization emitter (New Objective, Inc.). 1,300 V was applied via liquid 
junction. One survey scan (resolution of 60,000) was followed by three 
information-dependent product ion scans in the ion trap. 2+, 3+, and 4+ 
charged ions were selected for fragmentation.
The uninterpreted MS/MS spectra were searched against a small 
protein database containing the HDAC4 sequence using Mascot soft-
ware (Matrix Science). The algorithm was set to use no enzyme specific-
ity, assuming carbamidomethyl as a fixed modification of cysteine and 
PKA-dependent cleavage of HDAC4. The identified cleavage 
consensus site is unusual and lies in a hydrophobic pocket. It is 
tempting to speculate that PKA phosphorylation of HDAC4 
exposes the cleavage site.
HDAC4-NT is a potent repressor of MEF2 and is unrespon-
sive to CaMKII signaling. Thus, antagonistic kinase-signaling 
pathways converge on MEF2 to modulate its activity and,   
as a consequence, the transcriptional program for cardiac re-
modeling. In contrast to proteolytic processing by caspases, 
PKA-mediated proteolytic processing of HDAC4 does not reduce 
myocyte viability by modifying the specificity to target tran-
scription factors. This implies that HDAC4-NT could be car-
dioprotective in the course of chronic heart failure. Thus, 
gene therapeutic approaches that aim to overexpress HDAC4 
1–201 (NT) could be a novel means of therapeutic cardiopro-
tection and would increase the amount of MEF2-repressive 
modifiers in the nucleus. Based on the findings of this study, 
gene  transfer  of  HDAC4  1–201  (NT)  would  be  beneficial 
over  the  expression  of  a  nonphosphorylatable  constitutive 
nuclear HDAC mutant in adult hearts, which, as previously 
described, results in acute cardiac dysfunction (Czubryt et al., 
2003). Further in vivo studies are needed to test these promis-
ing possibilities.
Materials and methods
Chemical reagents and plasmids
Iso and dbcAMP were purchased from Sigma-Aldrich. AEBSF, KT5720, 
KN93, MG132, E64, EST, leupeptin, pepstatin A, proteasome inhibitor I, 
lactacystin, AM114, N-acetyl-leucinyl-leucinyl-norleucinal (ALLN), cal-
peptin, and Z-VAD(OMe)-fluoromethylketone were obtained from EMD, 
and MDL28170 was obtained from Enzo Life Sciences. Epitope-tagged 
derivates of CaMKII and class IIa HDACs containing N-terminal Myc or 
FLAG tags and C-terminal GFP tags were previously described (Backs et al., 
2006). HDAC4-GFP was cloned into pDsRed-Monomer-C1 (Takara Bio 
Inc.), resulting in an N-terminal RFP and a C-terminal GFP tag. HDAC4-
FL, HDAC4 2–201 (NT), and HDAC4 2–289 were cloned into p3×FLAG-
myc-CMV-24 (Sigma-Aldrich). Point mutations were introduced with the 
QuikChange kit (Agilent Technologies). Deletion mutants of HDAC4 were 
generated by PCR with PfuTurbo polymerase (Agilent Technologies). Myc-
PKA (catalytic  subunit of PKA, Prkaca) was a gift from O. Nakagawa 
(Kyoto University Graduate School of Medicine, Kyoto, Japan), and PKG 
was a gift from T. Lincoln (College of Medicine, University of South Alabama, 
Mobile, AL). An adenovirus harboring 3×MEF2-Luc was purchased from 
Seven Hills Bioreagents.
Mice
Mice lacking the catalytic  subunit of PKA, Prkaca, were previously described 
(Skålhegg  et  al.,  2002)  and  purchased  from  Mutant  Mouse  Regional   
Resource Centers.
Cell culture and transfection assays
COS cells were maintained in DME with 10% FBS, 2 mM l-glutamine, and 
penicillin-streptomycin. Transfection was performed with GeneJammer (Agilent 
Technologies) according to manufacturer’s instructions. H9c2 cells were trans-
fected with FuGENE HD (Roche) according to manufacturer’s instructions.
Cardiomyocyte isolation and adenoviral infection
NRVMs were isolated from 1–2-d Sprague Dawley rats as previously de-
scribed (Backs et al., 2006). After isolation, NRVMs were maintained in 
DME/199 medium (4:1) with 10% FBS, 2 mM l-glutamine, and penicillin-
streptomycin. NRVMs were infected 24 h after plating, grown 12 h later in 
serum-free media for another 4 h, and then stimulated with 100 nM ET1 for 
the indicated time period. Adenoviruses harboring FLAG-HDAC4-WT and 
FLAG-HDAC4-S/A were previously described (Backs et al., 2006), and 
adenoviruses harboring 3×FLAG-HDAC4 2–201 (NT) and 2–289 were 
generated according to the manufacturer’s instructions (ViraPower Adeno-
viral Expression System; Invitrogen).JCB • VOLUME 195 • NUMBER 3 • 2011   414
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